Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

Metformin Before Catheter Ablation for AF Helps Nondiabetic Patients With Overweight

News Conference News AHA 2025

Metformin Before Catheter Ablation for AF Helps Nondiabetic Patients With Overweight

November 18, 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

News Conference News AHA 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

November 17, 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients

News Conference News AHA 2025

DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients

Michael O'Riordan

November 09, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

November 18, 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

November 16, 2024

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

News Conference News AHA 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

November 16, 2023

Sudden Cardiac Death Declining Among NCAA Athletes

News Conference News AHA 2023

Sudden Cardiac Death Declining Among NCAA Athletes

Michael O'Riordan

November 15, 2023

Leadless Pacemaker Prototype Uses Heart’s Energy to Partly Power Device

News Conference News AHA 2023

Leadless Pacemaker Prototype Uses Heart’s Energy to Partly Power Device

Michael O'Riordan

November 11, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

What’s Going to Be Hot at AHA 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

November 07, 2023

Etripamil Nasal Spray in Paroxysmal SVT Speeds Conversion to Sinus Rhythm: RAPID

News Conference News AHA 2022

Etripamil Nasal Spray in Paroxysmal SVT Speeds Conversion to Sinus Rhythm: RAPID

November 07, 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

News Conference News AHA 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

Yael L. Maxwell

November 07, 2022

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

News Conference News AHA 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

November 19, 2021

Lariat LAA Ligation Doesn’t Boost Effect of AF Ablation: aMAZE Trial

News Conference News AHA 2021

Lariat LAA Ligation Doesn’t Boost Effect of AF Ablation: aMAZE Trial

November 18, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.